Is Iterum Therapeutics plc (NASDAQ: ITRM) Back In The Buying Zone?

    0
    96

    Armistice Capital LLC recently announced the acquisition of new stake in Iterum Therapeutics plc (NASDAQ:ITRM). The institutional investor has increased its shareholding in the Healthcare company by 25.02% to 1.11 million shares with purchase of 0.22 million shares. This fresh investment now brings its stake to 5.25% valued currently at $1.33 million. In addition, Abante Asesores Gestión SGIIC SA raised its holdings by 31351.0 to 66600.0 shares.

    With over 0.24 million Iterum Therapeutics plc (ITRM) shares trading Friday and a closing price of $1.04 on the day, the dollar volume was approximately $0.25 million. The shares have shown a negative weekly performance of -7.96% and its price on 07/31/20 lost nearly -0.95%. Currently, there are 14.87M common shares owned by the public and among those 10.40M shares have been available to trade.

    An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 4 analysts who have offered their price forecasts for ITRM have a consensus price objective of $4.00. The analysts have set the share’s price value over the next 12 months at a high of $9.00 and a low of $1.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Iterum Therapeutics plc stock is 3.00 for the next 12 months. But an upside of 88.44% will see the stock hit the forecast high price target while mean target price for the stock is $2.00.

    Insiders at the company have transacted a total of 6 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 3 of these insider trades were purchases, accounting for 19,961 shares. Insider sales of the common stock occurred on 3 occasions, with total insider shares sold totaling 1,589,903 shares.

    The top 3 mutual fund holders in Iterum Therapeutics plc are JNL Multi-Manager Small Cap Growt, Abante Global Funds – Biotech Fun, and Destra Granahan Small Cap Advanta. JNL Multi-Manager Small Cap Growt owns 0.16 million shares of the company’s stock, all valued at over $0.19 million. The company bought an additional 9700.0 shares recently to bring their total holdings to about 0.75% of the shares outstanding. Abante Global Funds – Biotech Fun bought 31351.0 shares to see its total holdings expand to 66600.0 shares valued at over $79254.0 and representing 0.31% of the shares outstanding. Destra Granahan Small Cap Advanta bought 566.0 shares to bring its total holdings to over 892.0 shares at a value of $1061.0. Destra Granahan Small Cap Advanta now owns shares totaling to 0.00% of the shares outstanding.

    Shares of Iterum Therapeutics plc (NASDAQ: ITRM) opened at $1.06, up $0.01 from a prior closing price of $1.05. However, the script later closed the day at $1.04, down -0.95%. The company’s stock has a 5-day price change of -7.96% and -71.89% over the past three months. ITRM shares are trading -76.89% year to date (YTD), with the 12-month market performance down to -84.22% lower. It has a 12-month low price of $0.92 and touched a high of $7.65 over the same period. Currently, 0.24 million shares have been traded, compared to an average intraday trading volume of 1.28 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -7.74%, -39.39%, and -60.25% respectively.

    Institutional ownership of Iterum Therapeutics plc (NASDAQ: ITRM) shares accounts for 42.90% of the company’s 14.87M shares outstanding. Mutual fund holders own 34.72%, while other institutional holders and individual stakeholders account for 7.35% and 1.07% respectively.

    It has a market capitalization of $22.36M. The earnings-per-share (ttm) stands at -$6.75. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.16% over the week and 6.70% over the month.

    Analysts forecast that Iterum Therapeutics plc (ITRM) will achieve an EPS of -$0.81 for the current quarter, -$0.66 for the next quarter and -$2.25 for 2021. The lowest estimate earnings-per-share for the quarter is -$1.07 while analysts give the company a high EPS estimate of -$0.56. Comparatively, EPS for the current quarter was -$1.93 a year ago. Earnings per share for the fiscal year are expected to decrease by -32.40%, and 34.10% over the next financial year.

    If you are looking to buy this stock, then you may note that the average analyst recommendation by 4 brokerage firm advisors rate Iterum Therapeutics plc (ITRM) as a “Hold” at a consensus score of 3.00. Specifically, 0 Wall Street analysts polled rate the stock as a buy, while 3 of the 4 advise that investors “hold,” and 1 rated it as a “Sell.”

    Looking at the support for the ITRM, a number of firms have released research notes about the stock. RBC Capital Mkts stated their Sector Perform rating for the stock in a research note on June 02, 2020, with the firm’s price target at $7-$2. Gabelli & Co coverage for the Iterum Therapeutics plc (ITRM) stock in a research note released on January 21, 2020 offered a Sell rating with a price target of . SVB Leerink was of a view on December 11, 2019 that the stock is Mkt Perform, while H.C. Wainwright gave the stock Buy rating on June 21, 2019, issuing a price target of $17.

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here